<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7048954/results/search/drug/results.xml">
  <result pre="first drugs used in combination with conventional pegylated interferon and" exact="ribavirin" post="therapies and significantly improved treatment outcomes.5–7 Second generation protease"/>
  <result pre="(&amp;gt;97% purity). All tetrapyrroles were dissolved in minimal volumes of" exact="Dimethyl sulfoxide" post="(DMSO) and diluted into culture media or assay buffers"/>
  <result pre="green Universal PCR Master Mix Protocol (Perkin Elmer Applied Biosystems," exact="Foster" post="City, CA). Quantitation was performed using the Comparative Cycle"/>
  <result pre="156 are &quot;hot spots&quot; for linear antivirals, such as first-generation" exact="telaprevir" post="and boceprevir. Additionally, mutations at position 156 also arise"/>
  <result pre="156 also arise after treatment with next-generation anti-proteases such as" exact="simeprevir" post="and grazoprevir.35 Enzyme constructs containing these mutations were tested"/>
  <result pre="ineffective against genotype 3. Three third-generation macrocyclics, glecaprevir, voxilaprevir and" exact="grazoprevir" post="were developed not only to target genotype 3 but"/>
  <result pre="drugs showed pan-genotypic inhibition of NS3 protease in vitro,39–41 however," exact="grazoprevir" post="was a significantly less effective inhibitor for genotype 3"/>
  <result pre="to function. Nature. 2005;436(7053):933–938. doi:10.1038/nature0407716107832 5.JacobsonIM, McHutchisonJG, DusheikoG, et al." exact="Telaprevir" post="for previously untreated chronic hepatitis C virus infection. N"/>
  <result pre="J Med. 2011;364(13):1195–1206. doi:10.1056/NEJMoa101049421449783 7.ShermanKE, FlammSL, AfdhalNH, et al. Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
  <result pre="safety of 12 weeks versus 18 weeks of treatment with" exact="grazoprevir" post="(MK-5172) and elbasvir (MK-8742) with or without ribavirin for"/>
  <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="for hepatitis C virus genotype 1 infection in previously"/>
  <result pre="safety of 8 weeks versus 12 weeks of treatment with" exact="grazoprevir" post="(MK-5172) and elbasvir (MK-8742) with or without ribavirin in"/>
  <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="in patients with hepatitis C virus genotype 1 mono-infection"/>
 </snippets>
</snippetsTree>
